Your Child Has Been Diagnosed with Bardet-Biedl Syndrome: A Parent's Complete Guide

Your Child Has Been Diagnosed with Bardet-Biedl Syndrome: A Parent's Complete Guide

Learning that your child has Bardet-Biedl Syndrome (BBS) is one of the most overwhelming moments a parent can face. You may be feeling shock, grief, confusion, or even guilt — and all of those feelings are completely normal. Many parents describe the period after diagnosis as a fog of medical appointments, internet searches, and unanswered questions. This guide is written to help you through that fog. It will explain what BBS means for your child, what you can do right now, what treatments are available today, and how to connect with a community of families who understand exactly what you are going through.

The most important thing to know right now: your child can live a meaningful, fulfilling life with BBS. The medical and research landscape has changed dramatically in recent years, with new treatments already approved and gene therapies advancing toward clinical trials. You have reason to hope.

Understanding Your Child's Diagnosis

Bardet-Biedl Syndrome is a rare genetic condition that affects approximately 1 in 100,000 to 1 in 160,000 children. It is caused by mutations in one of more than 26 known genes (BBS1 through BBS22, plus additional genes) that are responsible for building and maintaining cilia — microscopic structures on cells that act as sensory antennae. Because cilia are found throughout the body, BBS can affect multiple organ systems.

BBS is inherited in an autosomal recessive pattern. This means your child inherited one copy of a mutated gene from you and one from your other parent. Both parents are carriers — you each have one working copy and one non-working copy of the gene. Neither parent has BBS themselves. This is nobody's fault. With each pregnancy, carrier parents have a 25% chance of having a child with BBS, a 50% chance of having a carrier child, and a 25% chance of having a child with two working copies.

If you have other children, they may also be carriers or affected. Genetic testing can clarify this. A genetic counselor can help your family understand the implications and options.

How BBS May Affect Your Child

Every child with BBS is unique. The combination and severity of features varies considerably, even among siblings with the same mutation. Here is what to be aware of:

Vision: Progressive vision loss is the most consistent feature of BBS. It typically begins with night blindness in early childhood (often ages 4-8), followed by gradual loss of peripheral vision. This is caused by retinal dystrophy similar to retinitis pigmentosa. The rate of progression varies — some children retain useful central vision into young adulthood, while others experience faster decline. Early intervention with low vision services makes a tremendous difference in your child's ability to adapt.

Weight: Many children with BBS develop significant obesity beginning in infancy or early childhood. This is not caused by overeating or poor parenting — it results from disrupted hunger signaling in the brain due to ciliary dysfunction. The good news is that there is now an FDA-approved medication specifically designed to address this (see Treatments below).

Kidneys: Kidney abnormalities affect many children with BBS and can range from structural differences to progressive kidney disease. Regular monitoring with blood tests and ultrasounds allows early intervention if needed.

Extra Fingers or Toes (Polydactyly): Some children with BBS are born with extra digits. This is typically corrected surgically in infancy and rarely causes long-term issues.

Learning and Development: Some children with BBS experience developmental delays, learning differences, or speech delays. The range is wide — many children with BBS do well in mainstream education with appropriate support, while others benefit from specialized educational plans. Early intervention services (speech therapy, occupational therapy) can make a significant difference.

Other Features: Additional features may include hormonal differences affecting puberty, dental crowding, heart abnormalities, liver changes, and hearing differences. Your child's medical team will monitor for these over time.

Treatments Available Today

The treatment landscape for BBS has improved significantly in recent years:

FDA-Approved: Setmelanotide (Imcivree)

Setmelanotide (brand name Imcivree, by Rhythm Pharmaceuticals) was FDA-approved in June 2022 specifically for chronic weight management in BBS patients. As of December 2024, it is approved for children as young as 2 years old. It works by activating the MC4R pathway to restore proper hunger signaling. Clinical trials demonstrated meaningful reductions in both hunger scores and body weight. If your child struggles with obesity related to BBS, ask your endocrinologist about this medication. Rhythm Pharmaceuticals also offers a patient support program called Rhythm Cares to help with access.

Emerging: GLP-1 Receptor Agonists

Research published in 2025 suggests that GLP-1 receptor agonists (such as semaglutide) may also effectively treat BBS-related obesity by working through a different pathway. Case reports in pediatric BBS patients have shown promising results. This is an active research area — discuss with your child's endocrinologist whether this may be appropriate.

Gene Therapy Programs (For Vision)

Three gene therapy programs are advancing toward clinical trials for BBS-related retinal degeneration:

AXV-101 (for BBS1 mutations): Developed by Axovia Therapeutics and co-funded by A Race Against Blindness ($1.1M grant in January 2026). This therapy uses an AAV9 viral vector to deliver a working copy of the BBS1 gene directly to retinal cells. It has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation. A Phase 1 clinical trial (NCT07269665) is planned. Preclinical studies showed dose-dependent halting of retinal degeneration in mice carrying the most common BBS1 mutation (M390R).

BBS10 Gene Therapy: A collaboration between the University of Iowa (Dr. Arlene Drack), InVision 2020, and MeiraGTx/Eli Lilly. In a world first, three pediatric patients have received this AAV8-BBS10 gene therapy at St Helier Hospital in London (Aug 2025 – Jul 2026) through the UK MHRA Specials program — a compassionate access pathway for unlicensed medicines, not a formal clinical trial. The first NHS patient, an 11-year-old girl, was treated in July 2026. Patients travel to the University of Iowa for post-treatment evaluations. The program is evaluating safety and feasibility.

BBS7 Gene Therapy: Developed at Oregon Health & Science University (OHSU) by Dr. Martha Neuringer using a naturally occurring nonhuman primate model. Subretinal gene therapy slowed retinal degeneration and improved cone function in rhesus macaques.

These therapies target the retinal component of BBS specifically. While they are not yet available outside of clinical trials, they represent genuine hope for preserving or restoring vision in children with specific BBS mutations.

Multidisciplinary Care

The most effective approach to BBS management is coordinated care across multiple specialties. Your child's care team should include:

• Pediatric ophthalmologist or retinal specialist — monitoring vision, providing low vision referrals
• Pediatric endocrinologist — managing weight, growth, hormones, metabolic health
• Pediatric nephrologist — monitoring kidney function
• Clinical geneticist — confirming the mutation, genetic counseling
• Low vision specialist / Teacher of the Visually Impaired (TVI) — adaptive skills, assistive technology
• Dietitian — nutrition guidance tailored to BBS
• Developmental pediatrician or psychologist — supporting learning and development
• Speech-language pathologist — if speech or language delays are present

BBS Centers of Excellence

Several medical centers now offer specialized, coordinated BBS care. These centers understand the unique needs of BBS patients and can coordinate across specialties:

| Center | Location | Specialty Focus | Since |
|--------|----------|----------------|-------|
| Marshfield Clinic | Marshfield, WI | Multidisciplinary (30+ patients) | 2014 |
| Mayo Clinic | Rochester, MN | Endocrinology, Clinical Genomics | 2024 |
| Penn Medicine / CHOP | Philadelphia, PA | Ciliopathies, Genetics | 2022 |
| Our Lady of the Lakes | Baton Rouge, LA | Pediatric Obesity | 2024 |
| OU Health Sciences Center | Tulsa, OK | Adult Obesity Medicine | — |
| University of Iowa | Iowa City, IA | Ophthalmology, Gene Therapy | — |
| Lurie Children's / Northwestern | Chicago, IL | Pediatric Nephrology | — |

The UK BBS Clinic (founded by Prof. Philip Beales) has provided specialized BBS care since the early 2010s. Additional centers exist in the Netherlands, Norway, Germany, and France.

The Bardet-Biedl Syndrome Foundation maintains an updated directory at bardetbiedl.org/clinical-practice.

What to Do Right Now

These immediate steps will help you build a strong foundation for your child's care:

1. Complete genetic testing if not already done. Knowing the exact gene mutation (e.g., BBS1, BBS10) determines your child's eligibility for specific gene therapy trials and helps predict which features may be more prominent.

2. Get a comprehensive baseline evaluation. This should include a dilated eye exam with OCT imaging, kidney ultrasound and function tests, metabolic panel, hearing assessment, and developmental screening.

3. Contact a BBS Center of Excellence or ask your geneticist to help coordinate multidisciplinary care. Even if you cannot travel to a center regularly, many offer telehealth consultations or can guide your local team.

4. Request an IEP or 504 plan at your child's school if there are any vision, learning, or developmental concerns. A Teacher of the Visually Impaired (TVI) can be invaluable even before significant vision loss occurs.

5. Start low vision services early. Orientation and mobility training, Braille instruction, and assistive technology should begin while your child still has good vision — this makes adaptation much easier later.

6. Ask about setmelanotide (Imcivree) if your child is experiencing obesity. This FDA-approved medication is specifically designed for BBS-related weight gain.

7. Register with CRIBBS (Clinical Registry Investigating Bardet-Biedl Syndrome) at bbs-registry.org. This natural history registry helps researchers understand BBS progression and may connect your family with future clinical trials.

8. Connect with other BBS families. The BBS Foundation hosts an annual family conference and maintains online support groups. Meeting other families who understand your experience is one of the most helpful things you can do.

Supporting Your Child's Emotional Well-Being

A BBS diagnosis affects the whole family. Here are some guidance points:

• Be honest with your child in age-appropriate ways. Children sense when something is wrong, and honest information (delivered gently) builds trust.
• Focus on what your child CAN do, not limitations. Children with BBS develop remarkable adaptive skills when given the opportunity.
• Connect with peers. The BBS Foundation's family conferences include activities for children and teens. Meeting other kids with BBS can be transformative.
• Seek support for yourself. Parent support groups, counseling, and respite care are not luxuries — they are necessities. You cannot pour from an empty cup.
• Plan for transitions. As your child grows, help them develop self-advocacy skills. Teens with BBS should gradually take ownership of their medical care and understand their condition.

Community Resources and Support Organizations

• Bardet-Biedl Syndrome Foundation (BBSF) — bardetbiedl.org — Annual family conference, support groups, Centers of Excellence program, research funding
• BBS UK — bbsuk.org.uk — UK-based family support and information
• CRIBBS Registry — bbs-registry.org — Patient registry connecting families to research
• Foundation Fighting Blindness — fightingblindness.org — Largest private funder of retinal disease research
• A Race Against Blindness — araceagainstblindness.org — 501(c)(3) nonprofit funding sight-saving research for children, co-funder of AXV-101 gene therapy
• InVision 2020 — Funded BBS10 gene therapy research
• Rhythm Cares — rhythmtx.com — Patient support program for Imcivree access
• National Federation of the Blind — nfb.org — Youth programs, advocacy, scholarships
• American Foundation for the Blind — afb.org — Family resources, technology guides
• Family Connect — familyconnect.org — Resources specifically for parents of children with vision loss
• National Organization for Rare Disorders (NORD) — rarediseases.org — Rare disease advocacy and patient assistance programs

Clinical Trials Your Child May Be Eligible For

Active trials related to BBS (as of July 2026):

| Trial | Focus | Status | ID |
|-------|-------|--------|-----|
| AXV-101 Phase 1 | BBS1 retinal gene therapy | Not Yet Recruiting | NCT07269665 |
| MC4R Agonist Real-World Study | Setmelanotide outcomes | Recruiting | NCT07674290 |
| COBRA Cohort | BBS/Alström translational research | Recruiting | NCT04461444 |
| CRIBBS Registry | BBS natural history data | Recruiting | NCT02329210 |

Visit clinicaltrials.gov and search "Bardet-Biedl Syndrome" for the most current listings.

Looking Ahead with Hope

The BBS research landscape is more active and promising than at any point in history. Gene therapies are advancing toward human trials. An FDA-approved medication now addresses one of the most challenging aspects of BBS. New Centers of Excellence are opening. The community is growing stronger.

Your child's diagnosis is the beginning of a journey, not an ending. With coordinated medical care, early intervention, community support, and the remarkable resilience that children naturally possess, your child can thrive. The families who have walked this path before you are ready to welcome you, support you, and share what they have learned.

You are not alone. And there is real reason to hope.

---

This guide was prepared by ClearSight Research (education.araceagainstblindness.org), a free educational resource of A Race Against Blindness, a 501(c)(3) nonprofit funding sight-saving research for children with inherited retinal diseases. Last updated July 2026.